Rib Fracture Cryoanalgesia

Sponsor
Methodist Health System (Other)
Overall Status
Recruiting
CT.gov ID
NCT06093776
Collaborator
Pacira Pharmaceuticals, Inc (Industry)
10
1
24
0.4

Study Details

Study Description

Brief Summary

Rib fractures lead to poor patient outcomes and even death 3. Data suggests effective pain management is crucial to obtain favorable outcomes 4, 5Current outpatient treatment modalities are limited to oral or topical medications with low efficacy and high risk for opioid dependence. In-patient management with a thoracic epidural TEA is largely considered the gold standard, but the risks of TEA may outweigh the benefits 6 to 8.

Condition or Disease Intervention/Treatment Phase
  • Device: ioveraº system

Detailed Description

Methodist Dallas Medical Center MDMC is an urban Level I Trauma Center that manages over 200 rib fracture cases annually. MDMC has a history of developing and using innovative analgesia techniques aimed at improving outcomes. In 2010 we first described the need for advancements in the treatment of rib fracture patients 1. Later, we validated the technique that is now used at hundreds of trauma centers around the world 2. Our surgical and research teams have a history of advocating for optimal management of rib fracture pain in order to prevent serious complications.

This study will seek to describe the effective use of cryoanalgesia as a feasible method of pain management in the rib fracture patient. With a small cohort and case series, we will describe and refine the procedure and preliminary efficacy of the FDA-approved iovera system in adult rib fracture patients. In order to ethically assess the clinical relevance of the iovera system, our objective will be accomplished by completing a case series

Study Design

Study Type:
Observational
Anticipated Enrollment :
10 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Rib Fracture Cryoanalgesia
Actual Study Start Date :
Jun 5, 2023
Anticipated Primary Completion Date :
Jun 5, 2024
Anticipated Study Completion Date :
Jun 5, 2025

Arms and Interventions

Arm Intervention/Treatment
Case Series

Prospective: Case Series The investigators will complete ioveraº system training (i.e., cadaveric demonstration) and work with our local surgical team to develop an effective procedure. The technique will then be refined and considered fully developed with three consecutive successful placements. Data reporting to the sponsor will occur once data for the first five successful interventions and the subsequent 14-day follow-ups are completed. Adverse event reporting to the IRB will occur in accordance with GCP standards. Due to the small sample size and short duration, patients lost to follow-up will be an indication for additional enrollment. No more than 10 total subjects will be enrolled.

Device: ioveraº system
the use of surgical procedure that produces lesions in peripheral nervous tissue through application of extreme cold

Outcome Measures

Primary Outcome Measures

  1. Pain Assessment [14 days]

    Pain assessment using the Numeric Rating Scale for Pain NRS Pain McGill Pain Questionnaire [MPQ]), hospital LOS, ICU LOS, ventilator days, pain interference (using the Brief Pain Inventory [BPI]), sleep interference (using the Medical Outcomes Sleep Scale [MOS-Sleep]), sleep quality (using the Pittsburgh Sleep Quality Index [PSQI]), quality of life assessment [14], adverse events, re-admissions, and patient satisfaction [15].

Secondary Outcome Measures

  1. Demographics [30 days]

    Demographics age, sex, ethnicity, injury characteristics injury severity score ISS, abbreviated injury scale [AIS], mechanism, cause of injury), comorbidities, diagnoses, procedures, Glasgow Coma Scale (GCS) score (eye, verbal, motor, total), discharge status, discharge condition, emergency department and admission vitals, medication

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years of age Acute pain attributed to rib fracture(s) Able to obtain consent
Exclusion Criteria:
  • <18 years of age Pregnant Incarcerated Confounding injuries or significant pain attributed to secondary injury Patients with any of the following: cryoglobulinemia; paroxysmal cold hemoglobinuria; cold urticarial; Raynaud's disease; open and/or infected wounds at or near the treatment site

Contacts and Locations

Locations

Site City State Country Postal Code
1 Methodist Dallas Medical Center Dallas Texas United States 75203

Sponsors and Collaborators

  • Methodist Health System
  • Pacira Pharmaceuticals, Inc

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Methodist Health System
ClinicalTrials.gov Identifier:
NCT06093776
Other Study ID Numbers:
  • 057.GME.2021.D
First Posted:
Oct 23, 2023
Last Update Posted:
Oct 23, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 23, 2023